Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unjha FormulationsBOM:531762 +1.42%77 PB Ratio is 3.09 as of Aug. 21, 2026, which is 22% above its 10-year median of 2.53. GuruFocus rates BOM:531762 with a GF Score™ of 77/100 and a GF Value™ of ₹22.81 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 917 Drug Manufacturers companies, Unjha Formulations ranks worse than 68.16% on this metric.
Unjha Formulations Ltd stock PB Ratio (=3.21) is close to 1-year high of 3.21.
The historical rank and industry rank for Unjha Formulations's PB Ratio or its related term are showing as below:
BOM:531762'
s PB Ratio Range Over the Past 10 Years
Min: 1.35 Med: 2.53 Max: 11.4
Current: 3.09
During the past 13 years, Unjha Formulations's highest PB Ratio was 11.40. The lowest was 1.35. And the median was 2.53.
BOM:531762's PB Ratio is ranked worse than 68.16% of 917
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs BOM:531762: 3.09
During the past 12 months, Unjha Formulations's average Book Value Per Share Growth Rate was 22.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Unjha Formulations was 124.60% per year. The lowest was 8.60% per year. And the median was 21.05% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Unjha Formulations PB Ratio Related Terms
Unjha Formulations PB Ratio Historical Data
* Premium members only.
The historical data trend for Unjha Formulations's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unjha Formulations PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's PB Ratio distribution charts can be found below:
* The bar in red indicates where Unjha Formulations's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Unjha Formulations (BOM:531762) has a PB Ratio of 3.09 as of Aug. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Unjha Formulations and its competitors. This is 22% above median its historical median of 2.53. Over the past decade, Unjha Formulations' PB Ratio has ranged from 1.35 to 11.40. According to the industry distribution chart, Unjha Formulations ranks #625 out of 917 companies in the Drug Manufacturers industry, placing it in the top 68.2%.
Is Unjha Formulations' PB Ratio too high?
Unjha Formulations' current PB Ratio of 3.09 is 22% above median its 10-year median of 2.53. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 11.40. The Drug Manufacturers industry median PB Ratio is 1.97. Unjha Formulations' value of 3.09 is 56.9% above this industry median. Based on the distribution chart, Unjha Formulations ranks #625 out of 917 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Unjha Formulations has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Unjha Formulations' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Unjha Formulations ranks #625 out of 917 companies for PB Ratio. This places Unjha Formulations in the lower half of its industry. The industry median PB Ratio is 1.97. Unjha Formulations' value of 3.09 is 56.9% above this benchmark. Historically, Unjha Formulations' own PB Ratio has ranged from 1.35 to 11.40 over the past decade. While the company's 10-year median is 2.53 vs. the industry median of 1.97, Unjha Formulations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unjha Formulations's current PB Ratio of 3.09 is 56.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Unjha Formulations and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unjha Formulations's current PB Ratio is 3.09, which is 22% above median its own 10-year median of 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unjha Formulations stock overvalued right now?
Based on GuruFocus' analysis, Unjha Formulations (BOM:531762) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹22.81, compared to a current price of ₹26.50 — trading 16.2% above its estimated fair value. The current PB Ratio is 3.09, which is 22% above median its 10-year median of 2.53 and 56.9% above the Drug Manufacturers industry median of 1.97. Unjha Formulations' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Unjha Formulations (BOM:531762), the current PB Ratio is 3.09 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unjha Formulations (BOM:531762) Overvalued in 2026?
Based on GuruFocus' analysis, Unjha Formulations stock appears to be overvalued.
The current stock price of ₹26.50 is trading 16.2% above its estimated GF Value™ of ₹22.81.
GuruFocus considers Unjha Formulations to be Modestly Overvalued.
Key valuation signals for BOM:531762:
PB Ratio: 3.09 (22% above median its 10-year median of 2.53)
GF Value™: ₹22.81 vs. price of ₹26.50 (16.2% above fair value)
Industry Position: 56.9% above the Drug Manufacturers median (#625 of 917)
No single metric tells the full story. See the BOM:531762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.
77GF Score
Get the complete analysis for BOM:531762
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531762 has been successfully added to your 
